Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer

The goal of this clinical trial is to learn the safety of the addition of PULSAR radiation to standard of care chemotherapy and immunotherapy in people with esophageal and gastroesophageal junction cancer and to determine the safest dose of radiation that can be used. Participants in this study will be undergoing clinically scheduled procedures. In addition to the standard of care visits and treatments, there will be additional visits and assessments with radiation.

Trial Details

NCT ID
NCT07700420
Phase
PHASE1
Sponsor
University of Texas Southwestern Medical Center
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • PULSAR- Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy
  • FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)(D)
Locations (sample)
  • Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

  • At least 18 years of age at date of enrollment. Both men and women and members of all races and ethnic groups will be included.
  • Willing and able to provide written informed consent.
  • Pathologic diagnosis of esophageal or gastroesophageal junction adenocarcinoma. GEJ cancer includes Siewart types 1 and 2 tumors. Siewart type 3 is…
  • T1N+ or T2-4N(any) by the American Joint Committee on Cancer staging manual 8th edition

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →